Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Inclusion Criteria

• •Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
• •A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
• •Adult male or female between 18 and 80 years of age
• •Disease duration (time since diagnosis) \<10 years
• •Time since motor fluctuations ≤3 years
• •H\&Y Stage \<3 in best "on"
• •"off" time of 2.5-6 hours per day
• •Naïve to LDp/CDp
• •Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
• •Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
• •Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
• •Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered